Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092292 | 0.93 | NOTUM (0.39) | NOTUMPLATTLR9TLR8TLR7 | |
| SCHEMBL17547832 | 0.88 | KDM5A (0.41) | PLATPDE3BPDE3AKDM5A | |
| SCHEMBL16092521 | 0.86 | KDM5A (0.39) | NOTUMPLATPDE3BPDE3AKDM5A | |
| SCHEMBL17547841 | 0.85 | PLAT (0.41) | PLATTLR9TLR8TLR7KDM5A | |
| SCHEMBL17547833 | 0.84 | KDM5A (0.39) | PLATKDM5A | |
| SCHEMBL16092525 | 0.84 | KDM5A (0.40) | TLR8TLR7KDM5A | |
| SCHEMBL16092319 | 0.82 | PLAT (0.42) | PLATTLR9TLR8TLR7KDM5A | |
| SCHEMBL16092342 | 0.82 | KDM5A (0.40) | TLR9TLR8TLR7KDM5A | |
| SCHEMBL16092254 | 0.82 | KDM5A (0.55) | PLATKDM5A | |
| SCHEMBL16092244 | 0.81 | KDM5A (0.52) | PLATKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | NOTUM 1505/4885PLAT 4107/4885TLR9 3308/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | NOTUM 1505/4885PLAT 4107/4885TLR9 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.